Michael A. Tolle

Michael A. Tolle

Auto-generated profile, based on publicly available information

Michael A. Tolle

Botswana‐Baylor Children's Clinical Centre of Excellence Gaborone Botswana

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2012 in AIDS Care
Verified
Journal Article
Closed access
GWGelane Workneh
Gelane Workneh
LSLeah Scherzer
Leah Scherzer
BKBrianna Kirk
Brianna Kirk
HDHeather R. Draper
Heather R. Draper
GAGabriel Anabwani
Gabriel Anabwani
MTMichael A. Tolle
Michael A. Tolle
Clinical mentoring by providers skilled in HIV management has been identified as a cornerstone of scaling-up antiretroviral treatment in Africa, particularly in settings where expertise is limited. However, little data exist on its effectiveness and impact on improving the quality-of-care and clinical outcomes, especially for HIV-infected children. Since 2008, the Botswana-Baylor Children's Clinical Centre of Excellence (COE) has operated an outreach mentoring programme at clinical sites around Botswana. This study is a retrospective review of 374 paediatric charts at four outreach mentoring sites (Mochudi, Phutadikobo, Molepolole and Thamaga) evaluating the effectiveness of the programme as reflected in a number of clinically-relevant areas. Charts from one visit prior to initiation of mentoring and from one visit after approximately one year of mentoring were assessed for statistically-significant differences (p<0.05) in the documentation of clinically-relevant indicators. Mochudi showed notable improvements in all indicators analysed, with particular improvements in documentation of pill count, viral load (VL) results, correct laboratory monitoring and correct antiretroviral therapy (ART) dosing (p<0.0001, p<0.0001, p<0.0001 and p<0.0001, respectively). Broad and substantial improvements were also seen in Molepolole, with the most improvement in disclosure documentation of all four sites. At Thamaga, improvements were restricted to CD4 documentation (p<0.001), recent VL and documented pill count (p<0.05 and p<0.05, respectively). Phuthadikobo showed the least amount of improvement across indicators, with only VL documentation and correct ART dosing showing statistically-significant improvements (p<0.05 and p<0.0001, respectively). These findings suggest that clinical mentoring may assist improvements in a number of important areas, including ART dosing and monitoring; adherence assessment and assurance; and disclosure. Clinical mentoring may be a valuable tool in scale-up of quality paediatric HIV care-and-treatment outside specialised centres. Further study will help refine approaches to clinical mentoring, including assuring mentoring translates into improved clinical outcomes for HIV-infected children.

1 August 2011 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PPPremal Patel
Premal Patel
SDStephanie Davis
Stephanie Davis
MTMichael Tolle
Michael Tolle
VMVincent Mabikwa
Vincent Mabikwa
GAGabriel Anabwani
Gabriel Anabwani
The objective of this study was to assess the prevalence of hepatitis B and hepatitis C coinfections in human immunodeficiency virus (HIV) -infected adults at an HIV center in Gaborone, Botswana. A retrospective review was performed of charts of currently active HIV-infected adult patients in the Family Model Clinic (FMC) of the Botswana-Baylor Children's Clinical Center of Excellence (BCOE) in Gaborone, Botswana, for the results of serum hepatitis B surface antigen (HBsAg) and antihepatitis C IgG tests performed between January 1, 2005 and December 15, 2009. Of 308 active FMC patients, 266 underwent HBsAg serology testing within the period of study. The HBsAg coinfection prevalence was 5.3% (14/266); 2 of 252 patients had at least one positive antihepatitis C IgG serology, a 0.8% prevalence. Hepatitis B coinfection is relatively common in HIV-infected adults at our center in Botswana, whereas hepatitis C coinfection is rare. In this setting, where the diagnosis of hepatitis B coinfection with HIV has implications for choice of first-line antiretroviral therapy and prevention of perinatal hepatitis B transmission, broader sampling to establish the true population prevalence of hepatitis B coinfection and the desirability of adding screening to HIV management should be considered. These findings provide little justification for adding hepatitis C coinfection screening to the management of HIV infection in Botswana.

23 June 2009 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
MTMichael A. Tolle
Michael A. Tolle
Summary: Particularly in resource‐limited settings, HIV/AIDS is a family concern. Separate services for children and adults may make accessing care more difficult for families than services where family members can be cared for together. Implicit in comprehensive, family‐centred approaches to care are the broader notions of longitudinal primary care and linkages to other services, including those based in communities. As highly‐active antiretroviral therapy becomes more available, and the direct burden of HIV‐associated morbidity diminishes, HIV‐infected individuals require primary care that goes beyond exclusive management of HIV and related conditions, including preventive services and the management of common medical issues. The prevention of tuberculosis, diarrhoea, and, in endemic regions, malaria; the addressing of debilitating depression; cervical screening; and the management of chronic cardiovascular disease and its risk factors are all of benefit to patients accessing HIV/AIDS care. Packaging such services is an effective means both of standardizing care within a program and of ensuring patients receives a full roster of available interventions. As family‐centred care models develop in resource‐limited settings, the availability of evidence‐based service packages such as presented here will help program designers prioritize available human and materiel resources toward those interventions that improve patients’ global health and well being.

14 December 2011
Verified
Journal Article
Closed access
GMGadzikanani Monyatsi
Gadzikanani Monyatsi
PMPaul C Mullan
Paul C Mullan
BPBenjamin R Phelps
Benjamin R Phelps
MTMichael A Tolle
Michael A Tolle
Edwin MachineEdwin Machine
Edwin Machine
GAGabriel M Anabwani
Gabriel M Anabwani

4 January 2013 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
SDStephanie Davis
Stephanie Davis
PPPremal Patel
Premal Patel
ASAbid Sheikh
Abid Sheikh
GAGabriel Anabwani
Gabriel Anabwani
MTMichael A. Tolle
Michael A. Tolle
Background As life expectancy of HIV‐infected patients improves due to antiretroviral treatment (ART) and the importance of associated co‐morbidities and chronic diseases increases, preventive care will become increasingly important. Adaptation of existing preventive guidelines to local environments will become a priority for HIV treatment programmes. Methods Guidance from the World Health Organization, a focused evidenced‐based literature review, Botswana national guidelines, Botswana‐specific morbidity and mortality data and centre‐specific data were used to adapt a published general primary care package for limited‐resource areas to our centre's specific setting. Results The preventive care package contains recommendations on tuberculosis prevention, malnutrition, depression, cervical and breast cancer, hepatitis B coinfection, cardiovascular risk factors, external injury prevention, domestic violence screening, tobacco and substance‐abuse counselling, contraception and screening and treatment of sexually transmitted infections. Conclusion This preventive care package addresses the comprehensive health needs of HIV‐infected adults in the FMC in an evidence‐based manner. The process of combining clinic‐specific prevalence data, national guidelines, regional literature and assessment of public‐sector resources to adapt an existing general package could be utilised to develop similar guidelines in other resource‐limited locales.

4 October 2011 in Journal of the International Association of Physicians in AIDS Care
Verified
Journal Article
Closed access
PDF file
MTMichael Tolle
Michael Tolle
LHLeigh Howard
Leigh Howard
BKBrianna Kirk
Brianna Kirk
AGAndres Gomila
Andres Gomila
HSHeidi Schwarzwald
Heidi Schwarzwald
GAGabriel Anabwani
Gabriel Anabwani
Background Limited data are available on patterns of resistance mutations in pediatric patients in southern Africa, where HIV-1 subtype C (HIV-1C) predominates. Methods Retrospective chart review of pediatric patients. Nucleoside reverse transcriptase inhibitor (NRTI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations quantified from population-based sequencing genotypic resistance assay results taken at time of first-line antiretroviral therapy (ART) failure (first-line ART = stavudine [d4T] or zidovudine [ZDV] + lamivudine [3TC] + nevirapine [NVP] or efavirenz [EFV]). Results Total number of patients with resistance assays analyzed is 45. Nucleoside reverse transcriptase inhibitor-associated mutation frequencies noted were M184V (n = 41; 91.1%); thymidine analogue mutations (TAMs; n = 20; 44.4%); >1 TAM (n = 9; 20%); TAM-2 pathway (n = 10; 22.2%); TAM-1 pathway (n = 7; 15.6%); TAM-1 and TAM-2 pathways (n = 3; 6.7%); K65R (n = 2; 4.4%); Q151M (n = 1; 2.2%); and L74V (n = 0; 0%). Nonnucleoside reverse transcriptase inhibitor-associated mutation frequencies noted were associated with notable resistance to either/both NVP and EFV (n = 40; 88.9%); K103N (n = 15; 33.3%); ≥1 mutations associated with etravirine (ETR) failure (K101E, Y181C, and G190A; n =20; 44.4%); and ≥2 notable NNRTI mutations (n = 12; 26.7%). Conclusions In this cohort, low-genetic barrier mutations were common, as were TAMs, including more than 1 TAM. Mutations compromising nonthymidine analogue backbones were rare, suggesting that it is likely that children who fail first-line NRTI backbones containing d4T or ZDV/3TC would still respond to abacavir (ABC), didanosine (ddI), and, for adolescents, tenofovir (TDF). Our data support the empiric continuation of 3TC in second-line regimens.